STOCKS TELEGRAPH

Author: ST Staff

  • Predictive Oncology Inc. (POAI) stock surged in the premarket trading sessions; here’s why

    Predictive Oncology Inc. (POAI) stock surged in the premarket trading sessions; here’s why

    Predictive Oncology Inc. (POAI stock) shares have shown advancement in the stock price in pre-market by 20.19% to trade at the price of $1.25 at the last check. POAI stock shed -4.59% while previously closing the session at $1.04. The POAI stock volume traded 2.39 million shares. POAI stock shed by-39.18% in the past year, and in the past week jumped up by 0.97%. In the past three and six months, the POAI stock has shed -7.14% and added 49.40% respectively. Furthermore, Predictive Oncology is currently valued at $67.93 million and has 48.80 million outstanding shares.

    What you need to know about Predictive Oncology Inc.

    Predictive Oncology Inc. is a medical instruments manufacturing company that delivers healthcare products and services of various sorts. The company’s manufacturing and supply platform has been established in the market of USA. There are three operational segments of the company which include Helomics, Soluble and Skyline.

    The company’s product and service offerings include environmentally conscious systems that target the infectious fluids’ collection and disposal. These infectious fluids are post-used and discarded after surgical procedures and operative cares.

    Company provides specifically provides a device for this targeting of fluid collection and disposal known as STREAMWAY system which is a wall mounted completely mechanized framework that arranges suction of fluid/liquid giving a continuous performance to doctors while essentially removing the possibility of medical services laborers’ vulnerability to infectious liquids gathered during careful and other patient strategies, as well as exclusive cleaning liquid and filters to clients of its system.

    The organization likewise gives contract research organization (CRO) and AI-driven prescient models of tumor drug reaction to work on clinical results to help drug, demonstrative, and biotech enterprises; and dissolvable and stable details for proteins, including immunizations, antibodies, and other protein therapeutics, just as creates tumor models for exactness malignancy treatment and medication improvement. Its CRO administrations improve the viability of malignant growth treatment utilizing the force of computerized reasoning (AI) applied to sicknesses information bases. The organization sells its clinical gadget items straightforwardly to emergency clinics and other clinical offices through utilized salespeople, self-employed entities, and wholesalers. The organization was once known as Precision Therapeutics Inc. furthermore, changed its name to Predictive Oncology Inc. in June 2019. Prescient Oncology Inc. was fused in 2002 and is situated in Eagan, Minnesota.

     

    Expansion and improvement in the product services of POAI stock’s subsidiaries thanks to GMP facilities

    Predictive Oncology Inc. is expanding its operational capacity and growing into a diverse and improved portfolio through its subsidiaries. Recently it announced that its two wholly owned subsidiaries are planning to expand through the qualification and fabrication of GMP facilities. These two subsidiaries are known as Soluble Biotech Inc. and Tumor Genesis Inc.

    This expansion will lead to increased potential of customer base as well as more qualified and attractive for the prospects of long term collaborations. This GMP facility will allow the company to be able to open the platform and opportunity for the researchers that are using cancer cell’s own mechanisms to use and produce a target which may be expressed protein or biological target.

    This is specifically done because the GMP facility allows for the company to provide formulations that are directly accessible to researchers for direct use in the lab. This facility acts as a bridge to shorten the manufacturing and supply process by directly providing a ready-made solution. GMP facility can also allow Soluble Biotech to provide its chromatography kits to biotech and biopharma companies as final protein purification step for animal and human testing and trial.

  • iQSTEL (IQST) Stock Fell 3% Last Session, Why?

    iQSTEL (IQST) Stock Fell 3% Last Session, Why?

    The shares of iQSTEL Inc (OTCQB: IQST) closed down -3.03 percent on Tuesday at $0.7200, and have been trading between $0.6630 and $0.7890 on the day. iQSTEL stock rose more than 18.50 percent in the past month, with over 1.36 million shares traded. Three-month performance shows that IQST stock fell by 28.36%, with an average volume of 1.31M shares traded.

    IQST stock price has gained more than 720.07% over the last 12 months, reaching a high of $2.0000 with a $99.08M market cap. Investors took profits after IQST gained 34% following changes made to the board of directors.

    IQST’s board has undergone what changes?

    iQSTEL operates in 15 countries with leading-edge Telecommunication, Technology and Fintech Services. IQST is publicly-traded in the United States. IQST provides services to several industries, including telecommunications, electric vehicles (EVs), financial services, chemicals, and liquid fuel distribution. In addition to electric vehicles (EVs), IQST also offers Technology, Telecom, Blockchain, and Fintech divisions.

    Furthermore, IQST has international business-to-business and business-to-consumer relationships through its subsidiaries: Etelix, SwissLink, QGlobal SMS, SMSDirectos, Global Money One, IoT Labs, and itsBchain.  IQST has an extensive portfolio of products and services including from SMS, VoIP, international fiber-optic connectivity for 5G, Cloud-PBX, OmniChannel Marketing to EV products and Management System and Connectivity.

    iQSTEL announced the addition of three new board members on Monday.

    • All of the newly added members share with IQST a wealth of experience in telecommunications, technology, and the finance, legal, and regulatory management areas.
    • IQST will have majority independent Board Members as of July 1, 2021, which will exceed another of Nasdaq’s listing requirements and further the company’s upward climb.
    • A solid operational foundation base that generated revenue of over $44 million in 2020 continues to be the basis of IQST’s high growth telecommunications and technology business plan.
    • By 2021, IQST forecasts revenues of $60.5 million through the development of new products and services with high margins.

    IQST revenue growth:

    iQSTEL last week reported $6.47 Million in revenue for May 2021. In IQST’s preliminary accounting results for May 2021, revenue increased 16% over May 2020. For the first five months of the year through May 2021, IQST generated $24.6 Million in revenue.

    IQSTEL (IQST) is encouraged by the performance of all operating subsidiaries and is confident about meeting its $65 Million revenue target. After the close of Q2, IQST plans to provide an update on the company’s ongoing M&A campaign.

  • Borqs Technologies Inc. (BRQS) stock surged in the premarket trading hours; here’s why

    Borqs Technologies Inc. (BRQS) stock surged in the premarket trading hours; here’s why

    Borqs Technologies Inc. or (BRQS stock) has displayed a surge in the share prices by 27.63% in the premarket trading session which led it to trade at $1.27 at the last check. BRQS stock previously closed the session on Wednesday gaining 11.18% to $1.00. The BRQS stock volume traded 14.95 million shares, which according to the average daily volume of 3.18 million shares within the past 50 days, is very high. BRQS stock has shed -25.18% in the past year up to date, and in the past week, it has moved up by 13.74%. Furthermore, Borqs Technology is currently valued in the market at $89.06 million and has 115.16 million outstanding shares.

    Here’s all that you need to know about the operational portfolio of Borqs Technologies Inc.

    Borqs Technologies is a software application company that specifically works on designing and developing software services and products. This software development service establishes the platform for the company to provide Android-based smart connected devices as well as cloud services solutions. BRQS stock provides these two segments of product offering and operations in the market space of The People’s Republic of China, the United States of America, and internationally.

    The company android segment provides commercial grade Android platform software and service solutions which are targeted towards the vertical market segment. The android lead solutions platform is known as BorqsWare software. BorqsWare software consists of client based software known as BorqsWare Client software which is used in Android phones, tablets, different IoT devices, and watches. The Server software platform for cloud services allows customers to have free space in developing end-to-end services for their devices. The clientele base of the company includes Chipset manufacturers and sellers, manufacturers of mobile equipment, mobile operators and software/product solution for mobile connected devices for enterprise and consumer applications.

    The company has its origin in 2007 and has been headquartered in Beijing, China.

    Recent initiation of a contract with SkyCentrics for supply and delivery of CTA-2045 EcoPorts

    BRQS stock made a recent announcement regarding the initiation of delivery of a sales contract that had been made. This contract was made with SkyCentrics as the client that will have a supply and delivery from BorqsWare for cellular CTA-2045 EcoPort products.

    This contract was made during October 2020 in which SkyCentric and BorqsWare recognized each other as potential strategic partners and collaborated. SkyCentric brings about one of the leading machine learning and artificial intelligence services in the United States for open standard power grid optimization in the U.S. This company focuses on energy-efficient, carbon optimized, and air quality products and services for its projects and clients.

    The adoption of CTA-2045 EcoPorts is for the adoption of an important role in the upcoming new generations of smart cities. These smart cities use smart and electronic methods and sensors to keep aware of the status of their energy and power output and monitoring these outputs for better efficiency especially on the grid loads.

    Early selection of CTA-2045 EcoPort empowered water warmers has been in progress in low-pay multi-family sun-based solar energy and capacity networks in Hawaii. Business and private business sectors in structures and force matrix improvement can reach $154 billion constantly 2026, as per Verified Market Research in their investigation known as “Global Building Automation System Market Size By Technology, By System, By Application, By Geographic Scope And Forecast (Aug 2020).

  • What Motivated Athersys (ATHX) Stock To Surge In Premarket Session?

    What Motivated Athersys (ATHX) Stock To Surge In Premarket Session?

    In premarket trading, Athersys Inc. (ATHX) was up 10.64% at $1.56 and trading higher on the charts today. The Athersys share price fell -2.76 percent to close at $1.41 on Wednesday. A total of 1.24 million shares were traded, which is lower than the average volume over the last three months of 2.17 million. During the trading session, ATHX stock oscillated between $1.41 and $1.49. EPS ratio for ATHX was -0.45.

    ATHX was down -2.08% over the last five sessions, down -15.57% over the past month, and down -19.43% since the beginning of the year. In the case of ATHX, its 50-day moving average is $1.6156 and its 200-day moving average is $1.8607. At the moment, ATHX’s RSI stands at 32.62. The ATHX stock is rising after a new publication decodes the multistem mechanism of the company.

    What did that publication say?

    Athersys is a biotechnology company dedicated to the discovery and development of new therapeutic products designed to extend and improve human life. Athx is developing its MultiStem cell therapy product, an adult-derived stem cell product that can be purchased off-the-shelf.

    ATHX product is initially intended for use in cases of neurological, inflammatory, immune, cardiovascular, as well as other critical care conditions. There are also several trials evaluating this potential regenerative medicine product at ATHX. MultiStem cell therapy is being further developed toward commercialization with ATHX’s strategic partnerships and network of collaborations.

    Today, Athersys announced that its data gathered from preclinical research for several years have been published in the peer-reviewed journal Scientific Reports.

    • Multipotent Adult Progenitor Cells (MAPC), clinically called MultiStem (invimestrocel), was studied in four in vitro studies to examine how they modulate inflammatory responses.
    • A possible mechanism by which ATHX’s MultiStem halts inflammatory organ injury and promotes recovery following tissue injury involves promoting endogenous, immunoregulatory mechanisms, including Treg differentiation, proliferation, and phenotypic activity.
    • Athersys (ATHX) and its collaborators have published many scientific papers related to MAPC in recent years.
    • The results complement previous reports on Treg induction in preclinical animal models and in human volunteers participating in ATHX’s clinical development programs.

    Other developments around MultiStem:

    According to Athersys (ATHX), its partner HEALIOS KK (Healios) has recently completed the enrollment in the ONE-BRIDGE study in Japan evaluating MultiStem (invimestrocel) in patients suffering from acute respiratory distress syndrome (ARDS). Two cohorts of patients are involved in the ONE-BRIDGE trial.

    With cohort 1, ATHX’s MultiStem treatment will be evaluated for its safety and efficacy in patients suffering from pneumonia-induced ARDS. The objective of cohort 2 was to evaluate the safety of MultiStem treatment in five patients who had been induced ARDS by COVID-19. After analyzing the data, ATHX-partner Healios will make a subsequent announcement depending on the results, if desired.

  • Eagle Bulk Shipping (EGLE) stock plunged in the premarket trading hours; here’s why

    Eagle Bulk Shipping (EGLE) stock plunged in the premarket trading hours; here’s why

    In the premarket trading session, the Eagle Bulk Shipping Inc. (EGLE) shares had climbed down to-7.6% at the last check to trade at the price of $47.31. EGLE stock previously closed the session of Wednesday gaining 1.31% at the share price of $51.20. The EGLE stock volume traded 0.2 million shares, according to the average daily volume of 0.2 million shares within the past 50 days it was lower. In the past year up to date, EGLE stock had surged by 215.27% and in the past week had moved down by -3.76%. In the past three and six months, the stock had jumped 41.48% and had added 177.21% respectively. Further, Eagle Bulk Shipping Inc. is currently valued in the market at a total value of $658.43 million and has 11.73 million outstanding shares as of now.

    What you need to know about Eagle Bulk Shipping Inc.

    Eagle Bulk Shipping Inc. is a marine shipping company that specifically on transportation through oceans around the world for dry bulk cargoes. The company focuses on the production of chartering courses for transportation, operates the dry bulk vessels that transport a variety of bulk cargoes. EGLE stock owns its own fleet of vessels which totaled 45 vessels as of 31st December 2020. The company uses its fleet o transport bulk cargoes including iron ore, pet coke and coals, steel and cement, fertilizers, and forestry products. The clientele of the company includes a base of traders, end-user shipments, miners, etc. The company was founded in 2005 and is based in Stamford, Connecticut.

    Eagle Bulk announced a secondary public offering for a fund of collective shareholders at Golden Tree Asset Management LP

    The company had recently announced that EGLE stock is offering a secondary public offering which includes 1,695,182 shares of the common EGLE stock. The price of this secondary public offering is at $46.50 per share and is being collectively sold by shareholders of a certain fund and separate accounts managed by Golden Tree Asset Management LP. An additional 195,182 shares were placed to upsize the deal from 1,500,000 shares of common stock and additional 254,277 shares can be purchased by the underwriter. The time limit given for this additional offer option has been extended to the 30-days option. These additional shares will also be given by the collective Selling Shareholders. The offering is made pursuant to the company’s prospectus and related prospectus supplements. Furthermore, the date expected for the closing is on 2nd July 2021, according to satisfactory closing conditions.

    Morgan Stanley has been chosen as the sole book-runner for this offering however the proceeds of this transaction and public offering will not be taken by the company and will instead be received by the collective shareholders of the Golden Tree Asset Management LP. The intention of this offering as stated by the Eagle Bulk Shipping management is being made with the intent to comply with prospectus supplement and accompany the prospectus for the secondary public offering shareholders.

  • How Has The Tellurian (TELL) Stock Appreciated In Premarket Session?

    How Has The Tellurian (TELL) Stock Appreciated In Premarket Session?

    Tellurian Inc. (TELL) shares are up 4.49% at $4.42 in premarket trading on Wednesday. TELL stock finished last trading session down -4.08% at $4.23. TELL recorded a trading volume of 7.24 million shares, which is below the average daily volume of 16.4 million shares recorded over the last 50 days.

    Within the last five days, Tellurian shares gained 2.42%; however, over the last month, they lost -2.98%. Over the last three months, Tellurian stock price has increased 88.84%, and this year’s gain stands at 230.47 percent. After signing long-term leases with a port, Tellurian stock has gained.

    With whom did Tellurian sign its lease?

    Tellurian’s objective is to build a cost-competitive, global natural gas business and to deliver natural gas to customers around the world profitably. Tellurian is developing a pipeline and LNG export facility, as well as a natural gas production, trading, and marketing portfolio. Houston, Texas, is the home office of Tellurian.

    It was announced today that Tellurian’s 100 percent owned subsidiary Driftwood LNG LLC had executed its long-term lease option.

    • Tellurian subsidiary has exercised its option to lease the 477-acre site in Sulphur, Louisiana, from Lake Charles Harbor and Terminal District.
    • TELL’s ground lease agreement will initially last 20 years, with the option to extend for an additional 30 years.
    • Besides the long-term lease and several projects such as road improvement and utility relocation, Tellurian has begun taking necessary steps toward Driftwood LNG construction.
    • The Port of Lake Charles has been a helpful partner to Tellurian since the early development of its liquefied natural gas export terminal and site selection.
    • In appreciation for their hard work, the Lake Charles Harbor and Terminal District Board of Commissioners was thanked for their role in ensuring the success of Driftwood LNG.
    • Tellurian will bring over 6,500 construction jobs, 400 operational jobs, and millions of dollars in tax revenue and spending to Southwest Louisiana through Driftwood LNG.
    • Throughout its dynamic deepwater seaport, Tellurian will continue to support key developments that will benefit its citizens and community.

    Tellurian’s other strategic moves:

    Tellurian (TELL)’s other wholly owned subsidiary, Driftwood Pipeline LLC, submitted a formal application to the Federal Energy Regulatory Commission (FERC) last week. In the application, it was requested that Line 200 and 300, which is a dual 43-inch diameter interstate pipeline approximately 37 miles in length, be built.

    That pipeline will start in Beauregard Parish, Louisiana near Ragley and conclude in Calcasieu Parish, Louisiana, near Carlyss. As part of Tellurian’s overall commitment to support and balance the world’s energy needs and environmental concerns, this new and complete pipeline design provides definitive and measurable emissions reduction results.

  • Did Anything Boost EFIR Stock Last Trading?

    Did Anything Boost EFIR Stock Last Trading?

    As of yesterday’s close, EGPI Firecreek Inc (OTCPINK: EFIR) rose 7.14% to $0.0015. A total of 249.92M shares of EGPI stock were traded, in line with its average weekly volume of 251.75M. EFIR stock surged as it completed its preparation for the pink sheet current listing.

    How is EFIR handling the listing?

    By virtue of its wholly owned subsidiary Energy Producers, Inc., EGPI Firecreek has historically focused on acquiring existing fields with proven reserves. EFIR focuses on enhancing and improving oilfields with potential high growth in revenue and asset value. EFIR anticipates that it will continue to look for and acquire new revenue producing businesses with good growth potential as it seeks to extend its reach across a broad range of oil and gas businesses.

    EGPI Firecreek announced last week that it had completed the preparation for filing to up-list to a pink sheet status with OTC Markets.

    • According to OTC Markets procedures, EFIR has provided all of the documentation, including financial statements and one of the legal opinions as required.
    • In the event a filing is approved by OTCIQ, it will be posted on EFIR’s website within a few days for up-listing, and the OTCIQ system will upload it immediately after approval.
    • A recent update to EFIR’s corporate profile on OTCIQ also anticipates its pink sheet acceptance in a few weeks.
    • Additionally, EFIR reports that all previously issued convertible notes are barred from further collection or conversion activities due to current liability debts totaling $5,889,716 having passed the statute of limitations.
    • EFIR’s liabilities have been eliminated as of April 2, 2021 by an agreement, permanently canceling $2,876,628 of these obligations effect of which will be recorded in EFIR’s 2021 financial statements.
    • EFIR has filed its financial statements with the OTC Markets with footnotes that refer to these occurrences.
    • In addition to its ongoing discussions with a potential merger/acquisition candidate, EFIR plans to update shareholders on its activities and progress as it builds itself as a fully diversified oil and gas holding company.
    • The primary business of EGPI Firecreek (EFIR) has traditionally been oil and gas extraction and development.

    EFIR is on the right track:

    Efforts in EGPI Firecreek (EFIR) are focused on rehabilitation, production enhancements, and implementing state-of-the-art technology to upgrade proven reserves. Following the completion of its up-listing application, the focus of EFIR will now shift to developing a new corporate website and engaging in better transparency and communication through social media.

  • HUTCHMED (China) Ltd. (HCM) Stock Surges Following Listing on Hong Kong Exchange

    HUTCHMED (China) Ltd. (HCM) Stock Surges Following Listing on Hong Kong Exchange

    HUTCHMED (China) Ltd. (HCM) stock prices were up down by a minor 0.81% as of the market closing on June 29th, 2021, bringing the price per share down to USD$33.23 at the end of the trading day. Subsequent pre-market fluctuations saw the stock surge by 14.35%, bringing it up to USD$38.00.

    Hong Kong Listing

    The company had a massively successful first day of trading in Honk Kong, having been listed after a delayed previous attempt earlier in 2019. The earlier plan to list was shelved amid market uncertainties at the time. The biopharmaceutical company’s shares that were already trading on in the U.S and U.K jumped a massive 51%, with the company raising USD$537 million in their offering.

    Global Offering

    June 23rd2021 saw the company announce the pricing of its global offering which comprises an international offering and a Hong Kong public offering in connection with a primary listing of its ordinary shares on the Stick Exchange of Hong Kong Ltd.’s Main Board. The offering will see the sale of up to 104 million new ordinary shares of HCM.

    Pricing of Global Offering

    Both the International Offering and the Hong Kong Public Offering final offer price has been set at roughly USD$25.82 per American depositary share (ADS), with each ADS representing 5 ordinary shares of the company. The offer price was determined by the closing price of the company’s ADSs on the Nasdaq Global Select Market and shares on the AIM market of the London Stock Exchange on June 22nd, 2021. Shares are expected to begin trading on June 30th, 2021, pending approval from the SEHK.

    Offering Details

    The offering is expected to generate USD$0.54 billion in gross proceeds, before the deduction of expenses related to the offering. The agreement also comes equipped with an option for international underwriters to buy up to 15.6 million new issued Shares at the offer price, in case of over-allotments. This option is available for 30 days after the last day of lodging applications under the Hong Kong Public Offering.

    Allocation of Resources

    Net proceeds generated from the global offering are forecasted to be allocated towards the advancement of the company slate-stage clinical programs, as well as its pipeline of clinical-stage and preclinical stage candidates. This move serves to consolidate the company’s commercialization, clinical, regulatory, and manufacturing capability, as well as fund future opportunities and acquisitions.

    Future Outlook for HCM

    Armed with a solid liquidity position, HACM is poised to capitalize the added resources generated from its global offering. Current and potential investors are hopeful that management will continue to leverage the resources at their disposal to facilitate significant and sustained increases in shareholder value.

  • What Led The POWW Stock To Increase In Premarket Session?

    What Led The POWW Stock To Increase In Premarket Session?

    At last check, the shares of premier American ammunition and munition components manufacturer and technology leader, AMMO Inc. (POWW) rose 10.58% to $9.72 in premarket trade today. AMMO stock gained 3.05% to close at $8.79 in the last trading session. POWW stock volume, recorded at 4.94 million shares, was below the 2.37 million shares traded on average daily over the last 50 trading days.

    The POWW stock price has declined by 3.29% in the last five days; however, it had gained 28.13% over the last month. Over the past three months, POWW stock price increased by 55.85%, and it has gained 235.50 percent in the last 12 months. After the release of its financial results, the price of POWW stock has been rising.

    POWW’s performance: how did it fare?

    AMMO’s corporate headquarters are located in Scottsdale, Arizona. POWW designs and manufactures products for a number of applications, including law enforcement, military, sport shooting, and self-defense. With a vision of changing, innovating and energizing a complacent munitions industry, POWW was founded in 2016. POWW sells branded ammunition as well as /stelTH/ subsonic ammunition, armor-piercing rounds, and STREAK Visual Ammunition.

    AMMO released its financial results yesterday for the fourth quarter and the fiscal year ending March 31, 2021.

    Financial highlights:

    • Quarter-over-quarter, sales at POWW increased by 46%, an increase of $7.6 million.
    • As for margins, POWW’s fourth-quarter margin increased to approximately 23%, an increase of 179% or $7.1 million from the fourth quarter of last year.
    • By adding depreciation and amortization back to cost of goods sold, gross profit for POWW for the quarter increased to 27%.
    • In the quarter ended March 31, POWW’s operating expenses were 25% of sales, a decline of 58% from the previous year quarter.
    • The operating expense percentage of POWW for the year was 27%, a 61% decline from the previous year.
    • Approximately $3.4 million of the quarter’s non-cash expenses were incurred by POWW, which resulted in a net loss of about $463,000 for the company.
    • In addition to the $7.8 million net loss for the year, POWW incurred non-cash expenses of $10.1 million.
    • Adjusted EBITDA reached $4.8 million, up 296% from same quarter last year.
    • A 213% increase to $8.1 million in Adjusted EBITDA for POWW was reported for the year.
    • During its fiscal fourth quarter, POWW’s adjusted earnings per share (EPS) increased 167% year-over-year to $0.04.
    • EPS of POWW for the year rose to $0.07, which represents a 150% increase from the prior year.

    What does POWW see ahead?

    AMMO (POWW) is committed to establishing a new standard in its fiscal 2022, which should result in exceptional growth. Additionally, POWW has exhibited its ability to design and manufacture technologically advanced ballistic match ammunition for The United States Department of Defense.

  • AeroVironment, Inc. (AVAV) Stock Continues Downward Trend Following Disclosure of Q4 2021 Financial Report

    AeroVironment, Inc. (AVAV) Stock Continues Downward Trend Following Disclosure of Q4 2021 Financial Report

    AeroVironment, Inc. (AVAV) stock prices were down by 0.76% as of the market closing on June 29th, 2021, bringing the price per share down to USD$109.87 at the end of the trading day. After hours trading  saw the stock dip by another 4.43%, bringing it up to USD$105.00.

    Revenue Reports

    The company reported revenues for the fourth quarter of fiscal 2021 amounting to USD$136 million, up from the USD$135.2 million reported for the same time period of the prior fiscal year. The difference is largely attributable to a USD$15.8 million increase in revenue of the company’s Medium Unmanned Aircraft Systems (MUAS), as a result of the acquisition of Arcturus UAV in February of 2021.

    Partial Offsetting of Revenue

    The year-over-year increase in revenue was offset by a USD$15 million decrease in revenue of AVAV’s Unmanned Aircraft Systems (UAS) segment. This, in turn, was a result of a USD$14.2 million reduction in service revenue, as well as a decrease in product sales amounting to USD$0.8 million. The UAS segment consists of s the company’s existing small UAS, tactical missile systems and HAPS product lines, as well as the recently acquired Progeny Systems Corp’s Intelligent Systems Group (ISG).

    Gross Margins

    Gross margin for the fourth quarter of fiscal 2021 was reported at USD$59.7 million, up 12% from the USD$ 53.2 million reported for the prior year quarter. This difference was largely driven by a USD$8.8 million increase in product margin, while being partially offset by a USD$2.3 million reduction in service margin. Gross margins as a percentage increased fomr 39% to 44% over the course of the time period. This increase was primarily attributable to a favorable product and services mix.

    Income from Operations

    Q4 2021 income from operations was reported at USD$17.8 million, a USD$3.5 million decrease from the USD$21.3 million reported for Q4 2020. This difference is primarily driven by an increase in SG&A expenses in the amount of USD$8.5 million, as well as R&D costs having increased by USD$1.5 million. These increases were partially offset by a USD$6.5 million increase in gross margin. The increase in SG&A expenses was largely due to USD$3.3 million in acquisition-related expenses associated with the acquisitions of Arcturus UAV, ISG, and Telerob GmbH.

    Future Outlook for AVAV

    Armed with its recent string of potentially massively beneficial acquisitions, AVAV is poised to capitalize on the opportunities afforded to it as a result of its collaborations. Current and potential investors are hopeful that management will continue to leverage the resources at their disposal to facilitate significant and sustained increases in shareholder value.